精华制药(002349) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2018 was ¥326,250,102.78, representing a 7.54% increase compared to ¥303,374,731.47 in the same period last year[8] - Net profit attributable to shareholders for Q1 2018 was ¥60,093,236.10, an increase of 88.08% from ¥31,951,248.03 in the previous year[8] - The net profit after deducting non-recurring gains and losses was ¥59,782,300.65, up 92.71% from ¥31,021,366.99 year-on-year[8] - The basic earnings per share for Q1 2018 was ¥0.0715, an increase of 88.16% compared to ¥0.0380 in the same period last year[8] - The company expects net profit attributable to shareholders for the first half of 2018 to increase by 20.00% to 60.00%, ranging from ¥11,558.46 million to ¥15,411.28 million[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,368,286,543.31, a 3.91% increase from ¥3,241,587,925.29 at the end of the previous year[8] - The net assets attributable to shareholders at the end of the reporting period were ¥2,343,934,549.27, reflecting a 2.74% increase from ¥2,281,387,490.36 at the end of the previous year[8] - Accounts receivable increased by 33.11% to ¥391,651,486.74 due to the consolidation of Su Xin Pharmaceutical[15] - Prepayments surged by 101.67% to ¥24,442,737.72 primarily from increased advance payments for raw materials by Dongli Chemical[15] - Long-term deferred expenses rose dramatically by 1725.60% to ¥14,659,409.48 due to the inclusion of Su Xin Pharmaceutical in the consolidated financial statements[15] - Short-term borrowings increased by 58.00% to ¥79,000,000.00 as a result of the consolidation of Su Xin Pharmaceutical[15] Cash Flow - The net cash flow from operating activities for Q1 2018 was -¥15,033,706.80, an improvement of 74.38% from -¥58,685,656.16 in the same period last year[8] Expenses - Sales expenses grew by 51.91% to ¥47,953,569.26, attributed to an increase in sales personnel and related salaries[15] - Management expenses rose by 31.53% to ¥35,191,757.88 due to higher employee salaries and increased management costs from subsidiaries[15] - Financial expenses increased by 241.84% to ¥2,695,662.24, mainly due to increased interest payments on long-term borrowings by a subsidiary[15] Other Income - The company reported non-recurring gains of ¥310,935.45 during the reporting period[9] - Investment income rose by 252.22% to ¥672,070.78 due to improved performance from an associated company[15] - Other comprehensive income increased by 216.21% to ¥3,742,348.70, driven by the rise in the stock price of Kadmon in the U.S.[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,223[11] - The weighted average return on equity for Q1 2018 was 2.60%, up from 1.48% in the previous year, an increase of 1.12%[8]